220 related articles for article (PubMed ID: 12379721)
21. Genetic polymorphisms of group B streptococcus scpB alter functional activity of a cell-associated peptidase that inactivates C5a.
Bohnsack JF; Takahashi S; Hammitt L; Miller DV; Aly AA; Adderson EE
Infect Immun; 2000 Sep; 68(9):5018-25. PubMed ID: 10948119
[TBL] [Abstract][Full Text] [Related]
22. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine.
Baker CJ; Rench MA; McInnes P
Vaccine; 2003 Jul; 21(24):3468-72. PubMed ID: 12850362
[TBL] [Abstract][Full Text] [Related]
23. Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Wallerström G; Holmgren J
Vaccine; 2001 May; 19(25-26):3360-8. PubMed ID: 11348699
[TBL] [Abstract][Full Text] [Related]
24. [Comparative study of experimental conjugated and combined vaccines against group B streptococci].
Ditina MA; Meringova LF; Leont'eva GF; Frabovskaia KB; Yang A; Shen Z; Suvorov AN
Zh Mikrobiol Epidemiol Immunobiol; 2009; (1):37-41. PubMed ID: 19338234
[TBL] [Abstract][Full Text] [Related]
25. An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus.
Paoletti LC; Kasper DL; Michon F; DiFabio J; Holme K; Jennings HJ; Wessels MR
J Biol Chem; 1990 Oct; 265(30):18278-83. PubMed ID: 2120228
[TBL] [Abstract][Full Text] [Related]
26. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine.
Wessels MR; Paoletti LC; Rodewald AK; Michon F; DiFabio J; Jennings HJ; Kasper DL
Infect Immun; 1993 Nov; 61(11):4760-6. PubMed ID: 8406875
[TBL] [Abstract][Full Text] [Related]
27. A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.
Hillier SL; Ferrieri P; Edwards MS; Ewell M; Ferris D; Fine P; Carey V; Meyn L; Hoagland D; Kasper DL; Paoletti LC; Hill H; Baker CJ
Clin Infect Dis; 2019 May; 68(12):2079-2086. PubMed ID: 30281066
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III.
Baker CJ; Rench MA; Fernandez M; Paoletti LC; Kasper DL; Edwards MS
J Infect Dis; 2003 Jul; 188(1):66-73. PubMed ID: 12825173
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII.
Paoletti LC; Pinel J; Johnson KD; Reinap B; Ross RA; Kasper DL
J Infect Dis; 1999 Sep; 180(3):892-5. PubMed ID: 10438388
[TBL] [Abstract][Full Text] [Related]
30. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults.
Baker CJ; Rench MA; Paoletti LC; Edwards MS
Vaccine; 2007 Jan; 25(1):55-63. PubMed ID: 16919857
[TBL] [Abstract][Full Text] [Related]
31. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.
Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Edwards MS; Kasper DL
J Infect Dis; 2004 Mar; 189(6):1103-12. PubMed ID: 14999615
[TBL] [Abstract][Full Text] [Related]
32. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine.
Paoletti LC; Wessels MR; Michon F; DiFabio J; Jennings HJ; Kasper DL
Infect Immun; 1992 Oct; 60(10):4009-14. PubMed ID: 1398913
[TBL] [Abstract][Full Text] [Related]
33. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.
Paoletti LC; Rench MA; Kasper DL; Molrine D; Ambrosino D; Baker CJ
Infect Immun; 2001 Nov; 69(11):6696-701. PubMed ID: 11598040
[TBL] [Abstract][Full Text] [Related]
34. Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14.
Guttormsen HK; Baker CJ; Nahm MH; Paoletti LC; Zughaier SM; Edwards MS; Kasper DL
Infect Immun; 2002 Apr; 70(4):1724-38. PubMed ID: 11895934
[TBL] [Abstract][Full Text] [Related]
35. Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy.
Wessels MR; Paoletti LC; Guttormsen HK; Michon F; D'Ambra AJ; Kasper DL
Infect Immun; 1998 May; 66(5):2186-92. PubMed ID: 9573106
[TBL] [Abstract][Full Text] [Related]
36. Identification of novel adhesins from Group B streptococci by use of phage display reveals that C5a peptidase mediates fibronectin binding.
Beckmann C; Waggoner JD; Harris TO; Tamura GS; Rubens CE
Infect Immun; 2002 Jun; 70(6):2869-76. PubMed ID: 12010974
[TBL] [Abstract][Full Text] [Related]
37. Similarity between the group B and A streptococcal C5a peptidase genes.
Cleary PP; Handley J; Suvorov AN; Podbielski A; Ferrieri P
Infect Immun; 1992 Oct; 60(10):4239-44. PubMed ID: 1398935
[TBL] [Abstract][Full Text] [Related]
38. Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Infect Immun; 2000 Oct; 68(10):5749-55. PubMed ID: 10992481
[TBL] [Abstract][Full Text] [Related]
39. Glycoconjugate vaccines to prevent group B streptococcal infections.
Paoletti LC; Kasper DL
Expert Opin Biol Ther; 2003 Sep; 3(6):975-84. PubMed ID: 12943456
[TBL] [Abstract][Full Text] [Related]
40. Quantitative determination of antibodies to type III group B streptococcal polysaccharide.
Guttormsen HK; Baker CJ; Edwards MS; Paoletti LC; Kasper DL
J Infect Dis; 1996 Jan; 173(1):142-50. PubMed ID: 8537651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
